IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In reache application of:

MOSSELMAN ET AL.

Serial Number: 08/826,361

Group Art Unit: 1812

Filed: March 26, 1997

Examiner: M. Pak

For:

NOVEL ESTROGEN RECEPTOR

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR 1.97(b)

Assistant Commissioner of Patents Washington, D.C. 20231

November 24, 1997

Sir:

The attention of the Patent and Trademark Office is hereby directed to the document listed on the attached Form PTO-1449. This references was cited in the corresponding European application. A copy of this reference is submitted herewith.

No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the last of (1) issuance of a first official action on the merits and (2) expiration of the three month period following filing of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. It is respectfully requested that the information be considered during the prosecution of this application and that the cited documents be listed on the front page of any patent issuing from this application.

Mary Chamley 11/24/19

The Patent Office is authorized to charge our Deposit

Account No. 02-2334 for any fee which it deems to be required to effect consideration of this statement.

Respectfully submitted,

Mary E. Gormley

Attorney for Applicants Registration No. 34,409

Akzo Nobel Patent Department 1300 Piccard Drive Suite 206 Rockville, Maryland 20850

Tel: (301) 948-7400 Fax: (301) 948-9751

MEG:ms

N7moslmn.ids